Antiretroviral treatment for children with peripartum nevirapine exposure.

ABSTRACT:

Background

Single-dose nevirapine is the cornerstone of the regimen for prevention of mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings, but nevirapine frequently selects for resistant virus in mothers and children who become infected despite prophylaxis. The optimal antiretroviral treatment strategy for children who have had prior exposure to single-dose nevirapine is unknown.

Methods

We conducted a randomized trial of initial therapy with zidovudine and lamivudine plus either nevirapine or ritonavir-boosted lopinavir in HIV-infected children 6 to 36 months of age, in six African countries, who qualified for treatment according to World Health Organization (WHO) criteria. Results are reported for the cohort that included childre

SUBMITTER: Palumbo P 

PROVIDER: S-EPMC3021781 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature